• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Prothena Corporation plc

    2/14/24 12:16:26 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTA alert in real time by email
    SC 13G 1 d85927dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. ) *

     

     

    Prothena Corporation PLC

    (Name of Issuer)

    Ordinary Shares, $0.01 par value

    (Title of Class of Securities)

    G72800108

    (CUSIP Number)

    Diana L. Hayes, Esq.

    Trenam Law

    2700 Bank of America Plaza

    Tampa, Florida 33602

    813-227-7433

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    February 5, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ).

     

     

     


    CUSIP No. G72800108    Schedule 13G    Page 2 of 5 Pages

     

     1   

     NAME OF REPORTING PERSON

     

     Todd W. Fennell

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Florida

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0*

       6   

     SHARED VOTING POWER

     

     3,141,459*

       7   

     SOLE DISPOSITIVE POWER

     

     0*

       8   

     SHARED DISPOSITIVE POWER

     

     3,141,459*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,141,459*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     5.85%*

    12  

     TYPE OF REPORTING PERSON

     

     IN

     

    *

    See Item 4.


    CUSIP No. G72800108    Schedule 13G    Page 3 of 5 Pages

     

    Item 1.

     

      (a)

    Name of Issuer:

    Prothena Corporation PLC

     

      (b)

    Address of Issuer’s Principal Executive Office:

    77 Sir John Rogerson’s Quay, Block C

    Grand Canal Docklands

    Dublin 2, D02 VK60, Ireland

    Item 2.

     

      (a)

    The name of the Reporting Person is Todd W. Fennell.

     

      (b)

    The address of the Reporting Person is 979 Beachland Boulevard, Vero Beach, Florida 32963.

     

      (c)

    The citizenship of the Reporting Person is Florida.

     

      (d)

    Title and class of securities: Ordinary Shares, $0.01 par value

     

      (e)

    CUSIP No: G72800108

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 14 of the Act (15 U.S.C. 78o)
    (b)   

    ☐

       Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
    (c)   

    ☐

       Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
    (d)   

    ☐

       Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8)
    (e)   

    ☐

       An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E)
    (f)   

    ☐

       An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)
    (g)   

    ☐

       A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G)
    (h)   

    ☐

       A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
    (i)   

    ☐

       A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
    (j)   

    ☐

       A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J)
    (k)   

    ☐

       Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

    Not applicable

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    The Reporting Person may be deemed to be the beneficial owner of 3,141,459 Ordinary Shares. This amount consists of (i) 258,723 owned in the aggregate by various irrevocable gift trusts, for which the Reporting Person serves as an independent trustee, and (ii) 2,882,736 Ordinary Shares owned in the aggregate by various grantor retained annuity trusts, for which the Reporting Person serves as an independent trustee.


    CUSIP No. G72800108    Schedule 13G    Page 4 of 5 Pages

     

      (b)

    Percent of Class:

    According to the Issuer’s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, the number of shares outstanding as of October 26, 2023 was 53,665,349. The Ordinary Shares which the Reporting Person may be deemed to beneficially own constitute approximately 5.85% of such total number of shares. 

     

      (c)

    Number of shares as to which the Reporting Person has:

     

    i.   Sole power to vote or direct the vote:

         0  

    ii.  Shared power to vote or direct the vote:

         3,141,459  

    iii.   Sole power to vote or direct the vote:

         0  

    iv.   Shared power to vote or direct the vote:

         3,141,459  

    The Reporting Person disclaims beneficial ownership of all Ordinary Shares to which the Reporting Person does not have a pecuniary interest, and the Reporting Person expressly disclaims any status as a “group” with any other party.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.  

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. G72800108    Schedule 13G    Page 5 of 5 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2024 

     

    TODD W. FENNELL, individually

    /s/ Diana L. Hayes

    Diana L. Hayes, Attorney-in-fact*

     

    *

    Pursuant to a Limited Power of Attorney dated as of February 8, 2024, a copy of which is on file with the Commission.

    Get the next $PRTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRTA

    DatePrice TargetRatingAnalyst
    5/28/2025$4.00Neutral → Underperform
    BofA Securities
    5/27/2025Outperform → Perform
    Oppenheimer
    5/27/2025$6.00Buy → Hold
    Jefferies
    5/27/2025Overweight → Neutral
    Cantor Fitzgerald
    12/20/2024$40.00Buy
    Chardan Capital Markets
    1/30/2024$68.00 → $38.00Buy → Neutral
    BofA Securities
    12/12/2023$62.00Buy
    Deutsche Bank
    4/24/2023$80.00Outperform
    SVB Securities
    More analyst ratings

    $PRTA
    Financials

    Live finance-specific insights

    See more
    • Prothena to Report First Quarter 2025 Financial Results on May 8

      Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of deva

      5/1/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

      Net cash used in operating and investing activities was $47.8 million in the fourth quarter and $150.3 million for the full year of 2024; quarter-end cash and restricted cash position was $472.2 million The company expects cash guidance for the full year 2025 net cash used in operating and investing activities to be $168 to $175 million and expects to end the year with approximately $301 million in cash (midpoint) Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis being conducted under a SPA agreement with the FDA with a primary endpoint of all-cause mortality (time-to-event) at a statis

      2/20/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

      Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET. The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days. T

      2/13/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Scully William P received a gift of 430,000 units of Ordinary Shares, bought $2,749,916 worth of Ordinary Shares (207,436 units at $13.26) and gifted 747,700 units of Ordinary Shares, decreasing direct ownership by 7% to 735,993 units (SEC Form 4)

      4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

      5/2/25 10:29:05 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Welch Daniel G

      4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

      5/16/25 4:57:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Selkoe Dennis J.

      4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

      5/16/25 4:54:31 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kim Helen Susan

      4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

      5/16/25 4:52:37 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Prothena downgraded by BofA Securities with a new price target

      BofA Securities downgraded Prothena from Neutral to Underperform and set a new price target of $4.00

      5/28/25 8:10:50 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena downgraded by Oppenheimer

      Oppenheimer downgraded Prothena from Outperform to Perform

      5/27/25 9:09:16 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena downgraded by Jefferies with a new price target

      Jefferies downgraded Prothena from Buy to Hold and set a new price target of $6.00

      5/27/25 9:09:16 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

      Birtamimab did not meet the primary endpoint of time to all-cause mortality or the secondary endpoints Birtamimab development will be discontinued, including stopping the open label extension of the AFFIRM-AL clinical trial Company will decrease ongoing operating expenses, including an expected substantial reduction in organizational size, and plans to provide a further update in June Prothena Corporation plc (NASDAQ:PRTA) today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint (HR=0.915, p-value=0.7680). Based on these results, the Company will discontinue the development of birtamimab, including st

      5/23/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Reports First Quarter 2025 Financial Results and Business Highlights

      Net cash used in operating and investing activities was $53.4 million in the first quarter of 2025; quarter-end cash and restricted cash position was $418.8 million Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis being conducted under a SPA agreement with the FDA with a primary endpoint of all-cause mortality (time-to-event) at a statistical significance level of 0.10 Multiple clinical readouts for PRX012, a potential single-injection once-monthly subcutaneous treatment for millions of patients with presymptomatic or early symptomatic Alzheimer's disease, expected starting around mid-

      5/8/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena to Report First Quarter 2025 Financial Results on May 8

      Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of deva

      5/1/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

      SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

      11/14/24 1:22:34 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

      SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

      11/13/24 7:00:50 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

      SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

      11/13/24 6:06:27 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    SEC Filings

    See more
    • SEC Form 8-K filed by Prothena Corporation plc

      8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)

      5/23/25 4:33:24 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Corporation plc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)

      5/16/25 4:05:21 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plc

      SCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

      5/14/25 10:34:49 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

      Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million PRX012, a potential single-injection once-monthly subcutaneous treatment, is designed to address the unmet need of millions of patients with presymptomatic or early symptomatic Alzheimer's disease; Prothena expects to report multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials Results from partner Roche evaluating prasinezumab in patients with early Parkinson's disease from the Phase 2 PASA

      11/12/24 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Reports First Quarter 2024 Financial Results and Business Highlights

      Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million Advanced potential best-in-class Alzheimer's disease portfolio: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta/tau vaccine; Phase 2 clinical trial initiated in patients with early Alzheimer's disease for BMS-986446 (formerly PRX005) by partner Bristol Myers Squibb Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory

      5/8/24 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Appoints David Ford to Newly Created Chief People Officer Position

      Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has named David Ford to a newly created position of Chief People Officer, reporting to Prothena President and Chief Executive Officer Gene Kinney, PhD. In this role, Mr. Ford will be responsible for people, culture, and human resources strategy to drive the company's vision and overall growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240304692974/en/David Ford, Chief People Officer, Prothena (Photo: Business Wire

      3/4/24 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care